About

Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information - driven drug discovery, including GPCR structure determination.

The company’s lead program, RPC1063, is a best-in-class S1P1 small molecule agonist candidate for autoimmune indications. Receptos’ expertise in S1P1 biology has been informed by the company’s high resolution protein crystal structure of the S1P1 receptor, published in Science earlier this year. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc

Contact Info

10835 Road To The Cure, Suite 205, San Diego, CA, 92121
Tel: (858) 652-5700
www.receptos.com

Polaris Lead

Amir Nashat

Social Media